New drug LG-0317 tested in people for the first time
NCT ID NCT07522970
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study is the first time LG-0317 is given to humans. It involves 100 healthy Chinese adults aged 18-45 to check the drug's safety and how the body processes it. Participants receive either the drug or a placebo in single or multiple doses. The goal is to gather safety data before moving to larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LG-0317
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Xuhui Central Hospital
RECRUITINGShanghai, Shanghai Municipality, 200237, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults